In particular, protein kinases are of interest, since kinases are druggable molecules (Urbaniak et al., 2012), with an increasing number of kinase inhibitors used clinically to treat various cancers (Klaeger et al., 2017), and the possibility of repurposing human kinase inhibitors. This evidence concerns the gene WEE1 and cancer.